- Home
- ATLC vs MGTX Comparison
ATLC vs MGTX Comparison
Compare ATLC & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLC
- MGTX
- Stock Information
- Founded
- ATLC 1996
- MGTX 2015
- Country
- ATLC United States
- MGTX United States
- Employees
- ATLC N/A
- MGTX N/A
- Industry
- ATLC Finance: Consumer Services
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATLC Finance
- MGTX Health Care
- Exchange
- ATLC Nasdaq
- MGTX Nasdaq
- Market Cap
- ATLC 766.4M
- MGTX 622.0M
- IPO Year
- ATLC 1999
- MGTX N/A
- Fundamental
- Price
- ATLC $50.24
- MGTX $8.37
- Analyst Decision
- ATLC Buy
- MGTX Strong Buy
- Analyst Count
- ATLC 6
- MGTX 2
- Target Price
- ATLC $64.17
- MGTX $24.00
- AVG Volume (30 Days)
- ATLC 85.8K
- MGTX 563.1K
- Earning Date
- ATLC 08-07-2025
- MGTX 08-11-2025
- Dividend Yield
- ATLC N/A
- MGTX N/A
- EPS Growth
- ATLC 21.75
- MGTX N/A
- EPS
- ATLC 5.17
- MGTX N/A
- Revenue
- ATLC $424,877,000.00
- MGTX $34,508,000.00
- Revenue This Year
- ATLC $273.30
- MGTX $228.65
- Revenue Next Year
- ATLC $11.92
- MGTX $145.06
- P/E Ratio
- ATLC $9.74
- MGTX N/A
- Revenue Growth
- ATLC 17.71
- MGTX 203.23
- 52 Week Low
- ATLC $25.44
- MGTX $3.85
- 52 Week High
- ATLC $64.70
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- ATLC 39.47
- MGTX 62.96
- Support Level
- ATLC $45.74
- MGTX $8.32
- Resistance Level
- ATLC $53.12
- MGTX $8.95
- Average True Range (ATR)
- ATLC 2.48
- MGTX 0.40
- MACD
- ATLC -0.63
- MGTX -0.07
- Stochastic Oscillator
- ATLC 32.73
- MGTX 52.16
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.